
C. J. MALLIA* ET AL. (ASTRAZENECA, MACCLESFIELD, UK)

Control of Hydrogen Fluoride Formation and Release during a Large-Scale Nitroarene Reduction in the Manufacture of AZD9977

Org. Process Res. Dev. 2023, 27, 167–178, DOI: 10.1021/acs.oprd.2c00323.

Process Understanding Enables Control of Hydrogen Fluoride Formation in a Nitroarene Reduction



Significance: During the development of a synthesis to the nonsteroidal, selective mineralocorticoid receptor (MR) modulator **AZD9977**, Mallia et al. observed the unexpected formation of defluorinated byproduct **C** during the nitro reduction of nitrophenol **B** to aniline intermediate **A**. The formation of **C** was found to correlate with the formation of hydrogen fluoride (HF) which posed an environmental and safety hazard. The authors optimized the process to suppress HF formation during the reaction and implemented a basic reaction to sequester any residual HF generated which resulted in a scalable process to aniline intermediate **A**.

Comment: To minimize HF formation in the nitro reduction of **B**, the impact of all reaction parameters on the formation of **C** and by extension HF was studied. It was shown that reactions starved in H_2 , i.e., reactions with high Pd/C loadings, low H₂ pressure and low agitation (rpm), resulted in high levels of **C**. Severe etching of a glass coupon could be observed when a reaction solution of A was stored under air. This further suggested that oxidative decomposition of A likely proceeding via intermediate D could also release HF. For a 57 kg scale-up, reaction conditions minimizing the formation of **C** were selected and a LiOH quench was implemented to quench any HF generated such that the reaction stream of A after Pd/C removal could be used in the downstream chemistry without further purification.

Category

Innovative Drug Discovery and Development

Key words

nitro reduction

in situ HF formation

process safety



SYNFACTS Contributors: Antonia F. Stepan (Roche), Ferdinand H. Lutter (Janssen Pharmaceutica), Nadine Kuhl (MSD) Synfacts 2023, 19(04), 0407 Published online: DOI: 10.1055/s-0042-1752650; Reg-No.: A01623SF